in current cancer treatments. In human cancer, drug resistance is primarily associated with the overexpression of multidrug resistance gene 1 (MDR1). Therefore, the human MDR1 gene promoter may be a target for anti-MDR drug screening. Numerous methods to prevent MDR have been investigated. However, they have been proven to be clinically ineffective. Therefore, the aim of the present study was to investigate whether downregulation of nucleophosmin (NPM) demonstrates any effects on the reversal of MDR in hepatocellular carcinoma (HCC) cells. In the present study, two in vitro MDR HCC cell lines, HepG2/Adriamycin (ADM) and SMMC7721/ ADM, were established and the level of MDR was measured. The results demonstrated that NPM downregulation markedly reversed the effects of MDR in the model used. In addition, NPM downregulation reduced P-glycoprotein expression, as well as MDR1 expression. These results suggested that downregulation of NPM may be a novel and effective method of reversing the effects of MDR, and may be a potential adjuvant for tumor chemotherapy.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide (1) , and is currently the third leading cause of cancer-associated death (2) . The majority of patients with HCC are not suitable candidates for surgery as they are diagnosed at an advanced stage. Chemotherapy with cytotoxic drugs, including anthracyclines, fluoropyrimidines and platinum complexes, serve a significant role in the management of terminal HCC. However, patients with HCC often do not respond to chemotherapy due to the development of multidrug resistance (MDR). Therefore, research into the development of a safe and effective MDR reversal agent is urgently required.
Nucleophosmin (NPM) is a major nucleolar phosphoprotein that has been implicated in multiple cellular functions, including ribosomal protein assembly and transport (3, 4) , centrosome duplication (5-7), molecular chaperone activity to prevent protein aggregation (8, 9) and regulating the activity of the tumor suppressors p53 (10) (11) (12) and p14 ARF (13) (14) (15) . Previous studies have demonstrated that the level of NPM expression is markedly increased when cells are committed to mitogenesis (16, 17) . In addition, excessive NPM expression has been linked to cellular transformation and oncogenesis (18) . NPM overexpression is often observed in human cancers, including those of the stomach (19) , colon (20) , bladder (21) , prostate (22) , thyroid (23) , ovary (24) , myeloid and lymphoid cells (25) . It has been demonstrated that NPM overexpression in bladder cancer is independently associated with recurrence and progression to more advanced stages, which suggests that overexpression of NPM may be an important prognostic indicator for cancer recurrence (21) . These findings suggest that NPM may be involved in the regulation of cellular growth in normal and neoplastic cells. Thus, it may have potential as a clinical indicator in cancer patients (21) . However, it remains unknown whether NPM may regulate cellular growth in MDR HCC cell lines.
One of the most important and extensively studied mechanisms of MDR in cancer cells is the efflux mechanism, which is based on P-glycoprotein (P-gp) function (26, 27) . P-gp is a 170 kDa plasma membrane glycoprotein encoded by the human multidrug resistance gene 1 (MDR1) gene, which functions as an adenosine triphosphate (ATP)-binding cassette transporter (26) . P-gp is a drug efflux pump that removes a number of chemotherapeutic drugs from MDR cancer cells (27) . In addition to producing drug resistance at a cellular level, P-gp has also been demonstrated to alter the pharmacokinetics of numerous drugs and has been correlated with poor bioavailability (28) (29) (30) . Therefore, P-gp inhibition may lead to the reversal of MDR during treatment with chemotherapeutic agents, and may lead to successful chemotherapy results in patients with MDR tumors (31) . However, the association between P-gp and NPM in MDR HCC is currently unknown.
In the present study, the authors hypothesized that downregulated expression of NPM may increase the uptake and retention of chemotherapeutic agents via the inhibition of MDR1 expression and altered expression of P-gp in MDR HCC cells. Therefore, the aim of the present study was to investigate the cellular mechanisms of NPM-mediated reversal of MDR in HCC cells, which may re-sensitize the MDR HCC cells to chemotherapy. This novel strategy used the downregulated expression of NPM as a targeted tool in combination with chemotherapeutic agents for optimal therapeutic efficacy.
Materials and methods
Cell culture. The human HCC cell lines, HepG2 and SMMC7721, were purchased from the Institute of Biochemistry and Cell Biology (Shanghai Institutes for Biological Science, Chinese Academy of Sciences, Shanghai, China). HepG2 was cultured in Dulbecco's modified Eagle's medium (DMEM; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) and SMMC7721 was cultured in RPMI-1640 (Hyclone; GE Healthcare Life Sciences). The media were supplemented with 10% fetal bovine serum (FBS; Hyclone; GE Healthcare Life Sciences).
Multidrug resistance human HCC cell lines, HepG2/ADM and SMMC7721/ADM, were developed by the Department of General Surgery, Shanxi Dayi Hospital, Taiyuan, China). HepG2 and SMMC7721 cells were plated in a 6-well plate at a concentration of 2x10 6 in 2 ml of medium. To develop the HepG2/ADM and SMMC7721/ADM cells lines, ADM (Shanghai Pharmaceuticals Holding Co. Ltd, Shanghai, China) was added respectively to HepG2 and SMMC7721 cells at increasing concentrations from 0.01 to 0.2 mg/l over 10 months. MDR was maintained by culturing the cells in the presence of 0.2 mg/l ADM. MDR HCC cells were termed HepG2/ADM and SMMC7721/ADM. In addition, cells were cultured in the presence of the NPM inhibitor, NSC348884 (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). Cell lines HepG2/ADM+NSC348884 and SMMC7721/ADM+NSC348884 were cultured in DMEM or RPMI-1640 containing 10% FBS and 0.2 mg/l ADM, together with 1, 2, 3, 4, 5 or 6 µmol/l NSC348884. Cell proliferation was determined using a cell counting kit-8 assay (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). A total of 100 ul cell suspension was added into one well of a 96-well culture plate, and 10 ul CCK-8 was then added into the well to measure cell proliferation following medication, and absorbance was measured at a wavelength of 540 nm on a plate reader (PerkinElmer Wallac 1420 Victor2, Waltham, MA, USA). Data were expressed as the percentage of the survival of control, calculated from the absorbance and corrected for background. The half maximal inhibitory concentration (IC 50 ) was estimated by the dose of drug that resulted in 50% decrease in cell viability.
Flow cytometric analysis of cell cycle distribution. Cultured HepG2/ADM and SMMC7721/ADM cells and their parental cells were collected via trypsinization, washed with ice-cold PBS, centrifuged at 500 x g for 5 min at 4˚C, washed twice with ice-cold PBS and fixed in 70% ethanol for 2 h at 4˚C. Samples were rehydrated with PBS and the cells were incubated for 30 min at room temperature with a propidium iodide staining solution in PBS containing 0.2 mg/ml propidium iodide, 0.2 mg/ml DNAse-free RNAse A (Roche Diagnostics, Basel, Switzerland), and 0.1% Triton X-100. Using red propidium DNA fluorescence, 20,000 events were acquired with an Epics @ XL Beckman Coulter FACS machine (Beckman Coulter Inc., Brea, CA, USA) for each sample and the percentage of cells in G0/G1, S and G2/M phases of the cell cycle was calculated using the System Ⅱ™ software (Beckman Coulter Inc.) (32) .
Western blot analysis. The cells were lysed at 4˚C in a lysis buffer (Cell Signaling Technology Inc., Danvers, MA, USA). The cell lysates were centrifuged at 21,000 x g for 15 min at 4˚C. The protein concentration in the supernatant was detected using a BCA kit. Then proteins from tissue homogenate were loaded on sodium dodecyl sulfate-polyacrylamide gel (12% SDS-PAGE), transferred onto a polyvinylidene membrane, blocked with bovine serum albumin, and then incubated using the primary antibodies anti-NPM (catalog no. 3542; 1:1,000; Cell Signaling Technology Inc.), anti-MDR-1 (catalog no. 13342; 1:1,000; Cell Signaling Technology Inc.), anti-P-gp (catalog no. A10436R; 1:500; Beijing Solarbio Science & Technology Co., Ltd, Beijing, China) and anti-β-actin (catalog no. A10938R; 1:1,000; Beijing Solarbio Science & Technology Co., Ltd) at 4˚C, overnight. Membranes were washed three times and then incubated with horseradish peroxide -conjugated secondary antibody (catalog no. 7074S; 1:2,000; Cell Signaling Technology Inc.) for 40 min at room temperature. Specific antibody binding was detected using electrochemiluminescence (Chemi Doc XRS+ Imaging system, Bio-Rad Laboratories, Inc. Hercules, CA, USA). The abundance of western blot signaling was determined using the image analysis software (Chemi Doc XRS+ Imaging system, Bio-Rad Laboratories, Inc.). Western blot analysis was carried out as described previously (33) .
Reverse-transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.
RT-qPCR analysis was performed as described previously (33) . Cells were plated in a 6-well plate at a concentration of 5x10 6 in 2 ml of growth medium. Total RNA was extracted using TRIzol ® (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol. Two micrograms of total RNA was reverse-transcribed into first-strand cDNA using Mx3005P. The following primers were used: NPM forward, 5'-GCA GTC GAC GAC ACC AAC ATG GAA GAT TCG ATG GAC-3' and reverse, 5'-CGC GTT AAC AAG AGA CTT CCT CCA CTG-3'; MDR1 forward, 5'-GGG GTA CCC CAG TCT CTA CG-3' and reverse, 5'-CAA GCT TGT CCG ACC TGA AGA G-3'; β-actin forward, 5'-TAA AGG GCA TCC TGG GCT ACA CT-3' and reverse, 5'-TTA CTC CTT GGA GGC CAT GTA GG-3'. PCR was performed for 35 cycles, each cycle was comprised of a denaturation step at 94˚C for 45 sec, annealing at 50˚C for 45 sec and extension at 72˚C for 45 sec, prior to a final extension step at 72˚C for 10 min. As a control, the housekeeping gene β-actin was amplified and quantified. Relative quantification of target gene expression was conducted using the 2 -ΔΔCq method (34) . RT-qPCR analysis was repeated >3 times.
Statistical analysis. All of the data were processed using the statistical software SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Samples were analyzed in triplicate, and three independent experiments were performed. Data are expressed as the mean ± standard deviation, and differences between two groups were analyzed with the Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

Determination of MDR in HepG2/ADM and SMMC7721/ADM cells.
ADM is a chemotherapeutic agent that is used for the primary treatment of tumors, including HCC (35) . In the present study, ADM was applied to two HCC cell lines to generate MDR HepG2/ADM and SMMC7721/ADM cells. MDR HCC cell lines were generated over the course of 10 months. The IC 50 values of different anticancer drugs in HepG2/ADM and SMMC7721/ADM cells were significantly higher when compared with that of their parental cells (Table I) , and the CCK-8 assay revealed that HepG2/ADM and SMMC7721/ADM were not only resistant to ADM but also to multiple anticancer drugs, including DDP, 5-Fu, VCR and VP-16 (Table I ). These results suggested that acquired MDR of HepG2/ADM and SMMC7721/ADM was successfully established. NSC348884 downregulates NPM levels. It has been previously reported that NSC348884 is a specific inhibitor of NPM (36) . NSC348884 was used in the present study to determine whether downregulation of NPM reverses the MDR of HCC cell lines. MDR HCC cells were exposed to a variety of concentrations (1, 2, 3, 4, 5 or 6 µmol/l) of NSC348884. When cultured with ≤3 µmol/l NSC348884, HepG2/ADM and SMMC7721/ADM cells did not exhibit significant toxicity (Fig. 3) . However, when cultured with >3 µmol/l NSC348884, the cell survival rate of HepG2/ADM and SMMC7721/ADM cells markedly decreased (Fig. 3) . As shown in Fig. 4 , pretreatment of HepG2/ADM and SMMC7721/ADM cells with NSC348884, significantly decreased NPM protein and mRNA expression when compared t o t hat of t he pa r ent a l c el ls ( N PM p r ot ei n, HepG2/ADM+NSC348884 vs. HepG2/ADM, P<0.05; NPM protein, SMMC7721/ADM+NSC348884 vs. SMMC7721/ADM, P < 0 . Table I The effect of NPM on P-gp expression. In order to investigate the effect of NPM on P-gp expression, western blot analysis was performed (Fig. 6) . It was revealed that P-gp expression was significantly higher in HepG2/ADM and SMMC7721/ADM cells when compared with the parental cells (P<0.01 and P<0.01, respectively; Fig. 6 ). By contrast, when HepG2/ADM and SMMC7721/ADM cells were pretreated with NSC348884, P-gp expression was significantly reduced (P<0.01 and P<0.01, respectively; Fig. 6 ). Figure 3 . NSC348884 reduces the survival rate of multidrug resistant hepatocellular carcinoma cells. When ≤3 µmol/l NSC348884 was applied to HepG2/ADM and SMMC7721/ADM cells, no significant alterations in the rates of cell survival were observed. When >3 µmol/l NSC348884 was applied, the cell survival rates markedly decreased. Data are presented as the mean ± standard deviation of three independent experiments. ADM, adriamycin. 
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Discussion
MDR is characterized by the development of anticancer drug resistance, which may lead to the development of resistance to other pharmacokinetic and structurally unrelated drugs (37, 38) . For a number of years, MDR has been a major issue for scientists and clinicians in the treatment of cancer, however an effective solution has remained elusive.
Due to the difficulties encountered in the reversal of MDR, alternative methods to overcome MDR in cancer cells are continuously being investigated. Recently, NPM has received significant interest due to its association with ADM-resistant cells (39) . NPM, also known as B23, NO38 or Numatrin, is a 38-kDa estrogen-regulated nucleolar phosphoprotein that shuttles between the nucleus and cytoplasm (40) . NPM function has been implicated in a number of cellular processes, including ribosome shuttling between precursor proteins in the cytoplasm and nucleus, nuclear protein chaperone activity, the maintenance of genomic stability and the indirect regulation of growth and proliferation (39, 41, 42) . NPM overexpression has frequently been associated with tumor progression, and may be a marker for some cancers, including gastric, ovarian, prostate (42) and Ewing's sarcoma (43) . A previous study reported that NPM was highly expressed in human MDR gastric cancer cell lines (44), radiotherapy-resistant HeLa cells (45, 46) and in the MCF-7 breast cancer cell line where upregulated NPM expression enhances interferon regulating factor 1 mediated estrogen-resistance (47) . However, the effect of NPM downregulation on the reversal of MDR in HCC, as well as the underlying molecular mechanisms involved, remain unknown. Therefore, the present study was designed to investigate the effect of NPM downregulation on MDR, and the molecular mechanisms involved in this process. The results demonstrated that NPM expression was significantly increased in MDR HCC cell lines when compared to that of their parental cells.
To identify the mechanisms involved in the development of MDR in HepG2/ADM and SMMC7721/ADM cells, the cell cycle distribution was analyzed by flow cytometry. The percentage of MDR HepG2/ADM and SMMC7721/ ADM cells was markedly decreased in the G 0 /G 1 phase and increased in the S and G 2 /M phases when compared to their parental cells. This may have been responsible for the reduced cell proliferation ability (date not shown). In addition, delayed cell cycle progression may facilitate the removal of specific cytotoxic agents from the cell, thus leading to MDR in the cells.
An improved understanding of the possible molecular mechanisms and signaling pathways involved in MDR is important to overcome MDR and improve chemotherapeutic efficacy in patients with HCC. Multiple hypotheses have been proposed regarding the mechanisms underlying the development of MDR, including the involvement of P-gp, which is encoded by the MDR1 gene (26) . Previous studies have demonstrated that P-gp relies on the actin cytoskeleton for its localization in lipid rafts on the cell membrane, thereby influencing drug influx and possibly counteracting uptake (48, 49) . The action of P-gp as a drug efflux pump for therapies including ADM, docetaxel, paclitaxel and daunorubicin (50) , has led to the development of chemosensitizing agents including cyclosporine, verapamil and quinine, which competitively or noncompetitively inhibit this protein (51) . The expression of P-gp is increased in drug-resistant tumors of the colon, kidney and adrenal gland, as well as in some tumors that have acquired MDR following chemotherapy (52) . Excessive P-gp has been demonstrated to bind and transport anticancer drugs through ATP-dependent anticancer drug efflux pumps, leading to an increased efflux of the anticancer agent from the cancer cells, and a lower intracellular concentration (26, 31, 53) . The results of the present study demonstrated that P-gp expression was increased in MDR HepG2/ADM and SMMC7721/ADM cells when compared with their parental cells, indicating that MDR of HepG2/ADM and SMMC7721/ADM cells may be attributed to the overexpression of P-gp.
In order to further explore the role of NPM in the HCC MDR cell lines, NSC348884, a specific inhibitor of NPM, was applied to investigate whether downregulation of NPM may reverse MDR in HCC cell lines. Previous studies have demonstrated that application of NSC348884 suppressed the proliferation of prostate, colon, breast, lung and lymphoma tumor cells, thereby enhancing ADM sensitivity (36) . Following NSC348884 treatment of MDR HCC cells in the present study, cellular resistance to anticancer drugs was reversed, and corresponding alterations in the cell cycle distributions were observed. Further experiments suggested that NSC348884 may reverse MDR, via inhibition of P-gp function.
NSC348884 significantly reversed HCC MDR in the present study. The results implied that NSC348884 may be effective in reversing MDR in vitro. In addition, RT-qPCR and western blot analysis revealed that the expression of P-gp at the mRNA and protein level were decreased. Reduced expression of P-gp at the transcriptional and translational levels has been proposed to be one of the mechanisms for certain modulators or agents to reverse the MDR phenotype (54) .
In conclusion, the results of the present study have provided evidence demonstrating that NPM protein and mRNA levels were increased in HepG2/ADM and SMMC7721/ADM cells when compared to that of their parental cells. In addition, treatment of cells with a specific inhibitor of NPM (NSC348884) was able to reverse the MDR of HepG2/ADM and SMMC7721/ ADM cells, potentially via the downregulation of P-gp expression. The results suggest that NPM may be involved in MDR of HCC. It is a novel MDR reversal agent and may be a potential adjuvant agent for tumor chemotherapy. However, further research is required to optimize NPM exposure, and to determine the mechanisms underlying how downregulation of NPM leads to enhanced sensitivity of MDR HCC cells to anticancer drugs.
